Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 26Colorectal Neoplasms 9Neoplasms 7Carcinoma, Renal Cell 7Pancreatic Neoplasms 5Neoplasm Metastasis 5Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Melanoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Medullary 2Wilms Tumor 1Thrombocytosis 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

trebananib 1pembrolizumab 1lenvatinib 1camrelizumab 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Hepatocellular Carcinoma × cabozantinib × Gastrointestinal × Clear all
NCT04442581 2023-04-05

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

University of Washington

Phase 2 Terminated
2 enrolled 12 charts
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡